NCT02472392 (Ewing/Allo) is a Phase 1 clinical trial of Rabbit anti-thymocyte globulin in EWINGS SARCOMA, sponsored by University of Louisville.

Who is sponsoring NCT02472392?

NCT02472392 is sponsored by University of Louisville.

What drugs are being tested in NCT02472392?

Interventions in NCT02472392: Rabbit anti-thymocyte globulin, Busulfan, Melphalan, Fludarabine, Cyclophosphamide.

What condition does NCT02472392 study?

NCT02472392 studies EWINGS SARCOMA.

Is NCT02472392 still recruiting?

NCT02472392 is currently completed. Last updated 8 May 2017.

Last reviewed 2017-05-08 · How we verify

NCT02472392: Ewing/Allo

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study to Examine the Toxicity of Allogeneneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewings

Completed Phase 1 Last updated 8 May 2017

What this trial tests

Phase 1 trial testing Rabbit anti-thymocyte globulin in EWINGS SARCOMA in 10 participants. Completed in 1 December 2016.

Timeline

1 April 2013

Primary endpoint
1 December 2016

1 December 2016

Quick facts

Lead sponsor	University of Louisville
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 April 2013
Primary completion	1 December 2016
Estimated completion	1 December 2016
Sites	1 location across United States

Drugs / interventions tested

Rabbit anti-thymocyte globulin — full drug profile →
Busulfan — full drug profile →
Melphalan
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

EWINGS SARCOMA — all drugs for EWINGS SARCOMA →

Sponsor

University of Louisville

Who can join

Under 30, any sex, with EWINGS SARCOMA. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Toxicity assessed by safety labs and close monitoring from the study staff
Time frame: Over 5 Years
This will be assessed by safety labs and close monitoring from the study staff.

Sponsor's own description

The purpose of this study is to examine the toxicity of using allogeneic stem cell transplantation for treatment of subjects with relapsed or refractory ES and rhabdomyosarcoma. This is a nanrandomized two-arm study is designed to determine the safety and incidence of graft versus host disease (GVHD) in patients with relapsed, refractory Ewings sarcoma receiving related and unrelated, allogeneic stem cell transplants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Gene and Cell Therapy for Sarcomas: A Review.
Chawla SP, Pang SS, Jain D, Jeffrey S, et al · · 2025 · PMID 40227707 · DOI 10.3390/cancers17071125

Verify or expand the search:

Other trials of Rabbit anti-thymocyte globulin

Trials testing the same drug.

NCT07508787 — A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant · Phase 2 · not yet recruiting
NCT03249831 — A Blood Stem Cell Transplant for Sickle Cell Disease · Phase 1 · active not recruiting

Other University of Louisville trials

Trials by the same sponsor.

NCT07219888 — Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty · Phase 4 · not yet recruiting
NCT07044726 — Betadine vs Sterile Water for Periurethral Preparation · Phase 4 · not yet recruiting
NCT06489106 — Noninvasive Spinal Stimulation to Restore Hand Function in Children With Spinal Cord Injury · NA · enrolling by invitation
NCT06883513 — Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID · NA · recruiting
NCT05920720 — Self-Guided Personalized Treatment for Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02472392 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Louisville
Last refreshed: 8 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02472392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing